OneSource Specialty Pharma Partners with Formycon AG to Manufacture Biosimilars

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable glob…

OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing

Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing for Formycon’s biosimilar programs from its biologics facility in Bangalore

Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars

Open the article to view the coverage from NewMediaWire

Formycon and OneSource Specialty Pharma Forge Strategic Manufacturing Partnership for Biosimilars

Formycon AG and OneSource Specialty Pharma Limited have announced a strategic manufacturing partnership aimed at bolstering the production of biosimilars for global markets. Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing from its biologics facility in Bangalore, India, supporting Formycon’s biosimilar pipeline. The collaboration combines Formycon’s expertise in biosimilar development with One…

OneSource Specialty Pharma and Formycon AG announce strategic manufacturing partnership for biosimilars

OneSource Specialty Pharma, a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, “Formycon”), an independent biosimilar developer headquartered in Munich, announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its stat…